

Maintenance Treatment of Ulcerative Proctitis With Mesalazine Suppositories: A Double-Blind Placebo-Controlled Trial

Multicenter double-blind placebo-controlled trial.
Patients with UC proctitis in remission were randomized to 500mg mesalazine b.i.d; 500mg mesalazine i.d or placebo for 1 year.

Primary outcome: Relapse rate within 12 months

Results: N=111

- Relapse rates at 12 months were 10% 5ASA bid vs 32% 5ASA id vs 47% placebo, $p=0.007$ (5ASA bid vs placebo), $p=0.0334$ (5ASA bid vs 5ASA id)

Conclusion:

The results of this study confirm the therapeutic efficacy of mesalazine suppositories in the maintenance treatment of ulcerative proctitis. According to our experience the most effective therapeutic schedule is 500 mg mesalazine b.i.d

12 month Relapse Rate